（编辑 姚尧） 证券日报网讯 1月9日，雷迪克在互动平台回答投资者提问时表示，灵巧手是一种模拟人手结构与功能 的高性能末端执行器，具备高度灵活性与精准控制能力，能够复现人手的复杂动作，执行各类精细任 务，是人形机器人实现精细操作的核心部件，在商业、工业、生活等领域均具有广泛的应用场景。公司 于2025年11月战略投资上海傲意信息科技有限公司20.41%的股权。傲意科技成立于2015年，是国内少 有的同时掌握"脑机接口"+"机器人"两大技术的企业，主要产品覆盖智能仿生手、智能脑电图系统、可 穿戴外骨骼设备、机器人灵巧手等。在机器人灵巧手领域，傲意科技已与多家机器人主机客户构建了良 好的合作关系。 ...

► 文 观察者网心智观察所 1月初的A股交易大厅里，脑机接口（BCI）板块毫无征兆地掀起了一场海啸，三博脑科、爱朋医疗、创新医疗等一众概念股，在短短几个交易日内被巨量 资金死死封在涨停板上。 这并非是一场没有根基的泡沫游戏。引爆这颗情绪炸弹的导火索，是一条足以载入中国硬科技史册的消息：中国脑机接口领域的"隐形冠军"、被誉为"独 角兽"的强脑科技（BrainCo），刚刚完成了约20亿元人民币的巨额融资。这笔资金的量级震惊了业界——它不仅是除埃隆·马斯克旗下的Neuralink之外， 全球脑机接口领域规模第二大的单笔融资，更是一个极其明确的信号：脑机接口，这项长期游走在科幻电影与实验室小白鼠之间的"黑科技"，终于拿到了 通往工业化量产的"昂贵门票"。 对于蓝思科技而言，这是一场关乎生存维度的"换脑"手术。作为服务北美大客户比如苹果等超过10年的一级核心供应商，蓝思科技拥有着令全球制造业艳 羡的精密加工能力与产能规模 。但硬币的另一面是，智能手机与传统消费电子的红利正在肉眼可见地消退，增长的边际效应递减迫使巨头寻找第二条增 长曲线。 为什么是脑机接口？ 因为这是下一代人机交互的终极战场。如果说触摸屏改变了我们与数字 ...

Core Viewpoint - The article discusses the significant financing of 2 billion RMB for BrainCo, positioning it as a leading player in the non-invasive brain-computer interface (BCI) sector, contrasting it with Neuralink's invasive approach, highlighting the ongoing technological rivalry in the BCI industry [5][18]. Financing and Growth - BrainCo completed a financing round of approximately 2 billion RMB, led by IDG and Huaden International, making it the second-largest BCI company in terms of funding globally, after Neuralink [5][18]. - Since 2019, BrainCo has completed four financing rounds, accumulating a total of 4.684 billion RMB [15]. Technology Pathways - BrainCo focuses on non-invasive BCI technology, utilizing devices like EEG caps to collect signals, which offers safety and ease of acceptance, while facing challenges in signal precision [6][12]. - Neuralink represents the invasive BCI route, which involves surgical implantation of electrode arrays in the brain, allowing for high-resolution signal collection but poses risks and ethical concerns [5][12]. Product Development and Market Position - BrainCo has developed several products, including smart prosthetics and sleep regulation devices, with some receiving FDA and CE certifications for international sales [6][14]. - The company achieved a milestone in 2022 by producing 100,000 units of a portable high-precision BCI product, breaking the long-standing experimental phase in the industry [14]. Competitive Landscape - The BCI market is characterized by three main technological pathways: invasive, semi-invasive, and non-invasive, each balancing performance, safety, and accessibility differently [20][22]. - Non-invasive BCIs, led by companies like BrainCo, dominate the market, accounting for approximately 82% of the BCI market share, while invasive technologies hold about 18% [22].

Core Viewpoint - The article highlights the advancements in brain-computer interface technology through the example of Qiangnao Technology, which has developed a smart bionic hand that enables users to perform complex tasks, showcasing the potential for human-robot coexistence in the future [1][3]. Group 1: Company Overview - Qiangnao Technology, founded in 2015, is the first unicorn in the brain-computer interface sector in China, focusing on non-invasive brain-computer interface technology for nearly a decade [5]. - The company recently completed a financing round of approximately 2 billion yuan, making it the second-largest in the global brain-computer interface field after Neuralink [3]. Group 2: Product Development - Qiangnao Technology has launched several products, including smart bionic hands and legs, as well as brain-machine intelligent sleep devices, creating a product matrix that spans medical rehabilitation, consumer health, and advanced robotics [8]. - The smart bionic hand has been successfully used in major events such as the Beijing Winter Paralympics and the Hangzhou Asian Para Games, indicating its practical application and recognition [10]. Group 3: Technological Advancements - The company has developed a solid gel electrode that allows for convenient brain signal acquisition without the need for conductive paste, overcoming a significant barrier in non-invasive technology [7]. - Qiangnao's Revo 2 bionic hand, weighing only 383 grams, can exert a grip force of 50N and carry weights of up to 20kg, showcasing its advanced multi-modal tactile sensing capabilities [12]. Group 4: Competitive Advantage - Qiangnao Technology has established a unique technological and commercial moat through large-scale production and cost control, managing to reduce the cost of its smart bionic hand to one-fifth to one-seventh of similar products in Europe and the U.S. [15]. - The company has achieved mass production of 100,000 units of high-precision brain-computer interface products, demonstrating its capability for industrial-scale production [15]. Group 5: Future Vision - With the recent funding, Qiangnao Technology aims to accelerate technological iterations, expand into global markets, and deepen its product offerings in rehabilitation, health, and human-machine interaction [16]. - The company's strategic direction is evolving from addressing rigid medical needs to broader applications in health, targeting to assist 1 million individuals with physical disabilities and 10 million patients with Alzheimer's, autism, and sleep disorders within the next 5 to 10 years [18].

2022年的冬季残奥会上，失去左臂及大部分右臂的运动员贾红光，佩戴着智能仿生手，通过非侵入式脑 机接口技术识别大脑意图，顺利完成火炬交接和传递。 2025年的冬天，马斯克宣布，脑机接口公司"神经连接（Neuralink）"将启动大规模脑机接口输出，并计 划转向近乎全自动化手术，引爆全球医疗行业热度。 新年伊始，A股脑机接口概念板块接连两个交易日掀涨停潮，超50亿元资金流入。1月6日，近20只脑机 接口概念个股涨停或涨超10%，倍益康、三博脑科、爱朋医疗等多只个股股价超过2025年最高水平。 千亿美元市场风口 去年末，马斯克称，Neuralink将于2026年开始对脑机接口设备进行"大规模生产"，并同步推进流程高度 精简、几乎完全自动化的手术方案。这一方案有望避免传统侵入式设备的创伤性瓶颈，还可以实现效率 与成本的双向优化。 脑机接口（BCI）是连接大脑与外部设备实现信息交互的新型技术。机构整理显示，根据信号采集方 式，脑机接口可分为三类：侵入式，即通过手术将电极植入大脑皮层，信号质量高但风险大；半侵入 式，即电极植入颅骨下但不穿透皮层，平衡信号质量与安全性；非侵入式，即电极贴附头皮，操作简便 但信号易受干扰。 ...

记者丨雷若馨 编辑丨孙超逸 2022年的冬季残奥会上，失去左臂及右臂大部分的运动员贾红光，佩戴着智能仿生手，通过非 侵入式脑机接口技术识别大脑意图，顺利完成火炬交接和传递。 2025年的冬天，马斯克宣布，脑机接口公司"神经连接（Neuralink）"将启动大规模脑机接口 输出，并计划转向近乎全自动化手术，引爆全球医疗行业热度。 新年伊始，A股脑机接口概念板块接连两个交易日掀涨停潮， 超50亿元资金流入。 Wind数据 显示，最近三个交易日，脑机接口指数累计涨幅超过14%。 | 名称 | 现价 | 涨跌幅 ▼ | 换手率 | 市盈率 | 年初至今 | | --- | --- | --- | --- | --- | --- | | 美好医疗 | 41.49 | 19.81% | 20.53% | 75.1 | 72.52% | | 创新医疗 | 28.63 | 9.99% | 1.65% | -206 | 33.10% | | 开立医疗 | 28.56 | 3.48% | 2.34% | 185 | 8.10% | | 航天长峰 | 26.15 | 2.75% | 20.31% | -54.7 | 24.29% ...

Core Viewpoint - The article highlights the significant financing of approximately 2 billion RMB by Strong Brain Technology, marking it as the second-largest disclosed financing in the global brain-computer interface (BCI) sector after Neuralink, drawing attention from both capital markets and the industry [2][3]. Financing Overview - Strong Brain Technology completed a financing round of about 2 billion RMB on January 6, 2026, with a diverse investor base including financial investors, industrial capital, and strategic investors such as IDG, Huaden International, and Lens Technology [2][14]. - This financing round reflects a continued interest in Strong Brain Technology's existing technology routes and product advancements, indicating confidence in the company's future [3][15]. - The company has a history of securing substantial capital, having previously completed multiple financing rounds, including a 20 million USD B round in 2025 and a 30 million USD Pre-B round [13][14]. Company and Product Development - Founded in February 2015, Strong Brain Technology has evolved into a key player in the BCI field, focusing on non-invasive BCI technology [7][9]. - The company has developed high-precision EEG signal acquisition and analysis technologies, achieving mass production of solid gel electrode materials in 2017, which improved the stability and accuracy of EEG signal collection [9]. - Strong Brain Technology has launched several BCI-related products, including smart bionic hands and legs, and a brain-machine intelligent sleep aid, with some products receiving FDA and CE certifications for international market entry [11][12]. Clinical and Market Progress - Strong Brain Technology's smart bionic hand is the first BCI product in China to receive FDA approval, allowing it to enter over 30 countries and regions by 2025 [12]. - The company holds over 200 core patents in the BCI field, with approximately 60% being invention patents, positioning it favorably in the domestic patent landscape [12]. Policy and Industry Support - The Chinese government has issued implementation opinions to promote innovation and development in the BCI industry, aiming for breakthroughs in key technologies by 2027 and establishing a robust industrial ecosystem by 2030 [16][17]. - Local governments, including Beijing and Shanghai, have introduced action plans to accelerate the application of BCI technologies across various sectors by 2030 [18][19]. Standardization and Ecosystem Development - The National Medical Products Administration released the first industry standard for BCI medical devices, effective January 1, 2026, to unify terminology and support regulatory and industrial collaboration [22]. - Various regions are also advancing infrastructure development to support BCI product research and application [23].

当前，脑机接口技术正推开规模化应用的大门。 跨年前夜，当"钢铁侠"马斯克在社交媒体上宣布2026年"神经连接"（Neuralink）将"大规模生产"脑机接 口设备，并转向"更加精简和几乎完全自动化的外科手术流程"时，世界的目光再次聚焦这场将重塑人机 关系的科技狂想。 事实上，在这场全球科技竞赛中，中国不再是追随者——从十年前默默耕耘，到如今在非侵入式赛道引 领风潮，以杭州"六小龙"之一的强脑科技（BrainCo）为代表的中国力量，已站上国际舞台中央。其创 始人兼CEO韩璧丞，这位哈佛博士未毕业就创业的"疯狂科学家"，正带领强脑科技向世界展示一条迥异 于Neuralink的东方路径：不追求以手术刀撬开颅骨的"连接"，而致力于用算法与传感解开大脑信号 的"密码"。 这背后，究竟藏着怎样的故事？ 高中毕业后，这位东北少年踏上了一条不寻常的国际化科研之路。 在韩国科学技术院（KAIST），一次偶然的学术探寻让韩璧丞了解到美国匹兹堡大学一项开创性实验： 一只猴子可以通过脑机接口控制机械臂给自己喂食可口的香蕉。"如果人类能直接用意念操控机器将带 来怎样的革命？" 为了离这个问题的答案更近一步，韩璧丞于2011年加入位于美 ...

1月5日，A股新年开盘首日，脑机接口板块迎来"开门红"，概念指数盘中大涨超13%，登顶日内最强板块。板块内个股掀起涨停潮，倍益康实现30CM涨停， 三博脑科、翔宇医疗、美好医疗等斩获20CM涨停，岩山科技、国际医学、塞力医疗等多股强势封板，这一前沿赛道得到资本的追捧。 消息面上，马斯克近期明确给出脑机接口设备的量产时间表，他在社交媒体上表示，公司旗下脑机接口公司Neuralink将于2026年启动设备大规模生产，并采 用近乎全自动化的外科手术流程，通过电极丝直接穿过硬脑膜的创新方式，大幅降低手术创伤与风险，将手术时长从6小时缩短至20分钟内。截至2025年9 月，全球已有12名重度瘫痪患者植入Neuralink设备，累计使用时长超1.5万小时，首位植入者已能凭意念打字、玩游戏，临床数据充分验证了设备的安全性 与稳定性。按照规划，2026年该设备电极通道将增至3000个并开展盲视临床测试，2028年目标实现超2.5万个电极通道与全脑区域连接。 全球脑机接口领域的竞争格局已全面拉开，中美两国在不同技术路线上各展所长。美国在侵入式、半侵入式领域先发优势明显，除Neuralink外，OpenAI首 席执行官Sam A ...

在机器人灵巧手方面，其灵巧手已经成为国内人形机器人领域的"第一梯队"产品，合作企业超过200 家。 目前，傲意科技主要生产和销售的产品包括智能仿生手、智能脑电图系统、可穿戴外骨骼设备、机器人 灵巧手等。其中，傲意科技的智能仿生手是中国首款、全球第三款通过FDA和CE认证的高端义肢，销 售覆盖美国、中东、俄罗斯、乌克兰、印度等全球多个国家和地区。 格隆汇1月5日丨雷迪克(300652.SZ)近日在线上交流活动中表示，傲意科技成立于2015年，是国内少有 的同时掌握"脑机接口"+"机器人"两大技术的企业，通过神经接口、机器人核心零部件等底层技术，多 年专注于神经康复医疗、智能辅具、大健康消费电子、机器人零部件和控制系统等业务板块。 ...